Biocytogen

🎖️ This Memorial Day, Biocytogen joins our communities in reflecting on the values of courage, dedication, and gratitude. ❤️🤍💙 From all of us at Biocytogen and Bickey, we wish you a meaningful Memorial Day marked by remembrance, gratitude, and reflection. #MemorialDay #RememberAndHonor #Biocytogen #Biotech #GlobalHealth

✨ We’re excited to take part in UK Biotech Day in London. UK Biotech Day brings together key leaders across the biotech ecosystem. Join us to learn how Biocytogen’s antibody discovery platforms, humanized models, and integrated preclinical solutions are supporting next-generation programs and research innovation. 📅 May 27–28, 2026 📍 Radisson Hotel & Conference Centre London Heathrow, London, UK If you’ll be attending, come say hello 👋 We’d love to connect and explore opportunities to collaborate. #Biocytogen #UKBiotechDay #Biotechnology #LifeSciences #BiotechNetworking #AntibodyDiscovery #DrugDiscovery

✈️ We’re heading to BIO Partnering for Oncology in Chicago! Biocytogen is excited to attend BIO Partnering for Oncology, taking place May 28–31 at Revel Motor Row, Chicago. We will showcase our next-generation antibody discovery platform, RenSuper, designed to transform antibody discovery through a fully digital, AI-enabled workflow—enabling the rapid design, review, and validation of complex molecules. 💡 We look forward to connecting onsite to discuss potential collaborations. 💬Schedule a meeting with us on the BIO Partnering platform #Biocytogen #Oncology #Biotech #AntibodyDiscovery #DrugDiscovery #AIDrugDiscovery #ImmunoOncology #TranslationalResearch #Biologics #BiotechInnovation #LifeSciences #Partnering

✨ Get ready for #AETEU 2026 in Basel, Switzerland! 🗣 Join us for our Oral Presentation to learn more about our First-in-Class Asset— BCG048, a Novel Bispecific Dual-payload ADC Targeting ITGB6 and B7H3, Exhibited Potent Efficacy in Patient-derived Tumor Xenograft Models. ⏰ May 29 | 10:00–10:15 AM 🎤 Guoli Zheng, Associate Director, Business Development - Licensing 📃 We will also be presenting posters on Poster Board 38  ⏰ Poster Viewing Hours: • May 27: 6:45 AM–6:45 PM • May 28: 7:15 AM–5:55 PM • May 29: 8:00 AM–3:45 PM Stop by Booth 22 during networking breaks and lunch to learn more and connect with our team. We look forward to seeing you in Basel! #Biocytogen #AETEurope #AntibodyTherapeutics #ADC #BispecificAntibodies #Oncology

🚀 First-in-Class, Safety-Improved Fully Human Nectin-4 × TROP2 Bispecific ADC for Urothelial Cancer While Nectin-4 and TROP2 have each demonstrated strong clinical validation in urothelial cancer (UC), current therapies are still challenged by dose-limiting toxicities and emerging resistance. 🎯 We strategically designed BCG039 to address these limitations through dual-target engagement and a differentiated safety design featuring attenuated TROP2 affinity binding. Developed using Biocytogen’s RenLite® platform, BCG039 incorporates a common light chain design to support streamlined manufacturability and favorable developability properties. 🔬 Key Highlights: ► Strong dual-target binding and cooperative internalization ► Attenuated TROP2 affinity design with potential safety advantages ► Superior and sustained tumor suppression in preclinical models ► Potential for an improved therapeutic window in UC treatment BCG039 represents our continued commitment to advancing next-generation bispecific ADCs designed to balance efficacy and safety for patients with urothelial cancer. 📩 Contact us to request the full data package: https://lnkd.in/eXHGT_Pp #Biocytogen #ADC #BispecificADC #Oncology #AntibodyDiscovery #DrugDevelopment #UrothelialCancer

💡 Webinar: RenNano Heavy-Chain-Only Antibodies Powering BBB Crossing, Multispecific Antibodies, ADCs, and In Vivo CAR-T Conventional IgG antibodies often fall short against “impenetrable” targets such as dense solid tumors and the blood–brain barrier (BBB). Join Dr. W. Frank An, VP of Institute for Biologics, to explore Biocytogen’s RenNano platform, designed for direct in vivo generation of fully human, high-diversity heavy-chain-only antibodies (HCAbs) and VHHs with extended CDR3 regions—enabling precise structural fit to challenging epitopes and unlocking new therapeutic possibilities. 📅 Date & Time: May 27, 2026 | 11:00 AM ET  🔗 Register here: https://lnkd.in/eD7jaHWc 🎯 What You’ll Learn: • In vivo generation of fully human HCAbs & VHHs via RenNano® • Design principles for BBB penetration and deep tissue targeting • Applications in multispecifics, ADCs, and in vivo CAR-T • Case studies showcasing functional and therapeutic potential #Webinar #Biocytogen #RenNano #AntibodyDiscovery #HCAb #VHH #BBB #ADC #CAR_T #MultispecificAntibodies #DrugDiscovery #Biotech #TranslationalResearch

🍪 A Sweet Break That Brings the Team Together🍦 ☀️Biocytogen enjoyed a little afternoon treat with Cookie Monstah for a refreshing summer break. 😋 Taking a few moments to step away and share some laughs always brings extra energy and good vibes to the day. 🔬 Here’s to continuing to build a culture where collaboration, science, and everyday wellbeing come together. #Biocytogen #Biotech #LifeScience #WorkCulture #CompanyCulture #TeamCulture #BiotechCommunity

 🐭Beyond GLP-1: Humanized Mouse Models for Next-Gen Metabolic Therapeutics Metabolic disease drug development is evolving beyond single-pathway approaches toward multi-target biology and metabolic resilience — from obesity to MASH. While GLP-1-based therapies have transformed the treatment landscape, the field is now advancing toward broader therapeutic goals, including lean mass preservation, metabolic health, and durable weight management. Next-generation strategies are expanding the field: 🔬 Multi-receptor agonists (GLP-1/GIP, GLP-1/GCGR, triple agonists) 🔬 Emerging targets including INHBE and GPR75 🔬 RNA-based therapeutics for precise pathway modulation                                                              To support these advances, predictive in vivo models are becoming increasingly important. Our humanized mouse model portfolio is designed to provide clinically relevant insights and support the next generation of metabolic therapeutic development. 📩 Get in touch: https://lnkd.in/eXHGT_Pp #Biocytogen #MetabolicDisease #ObesityResearch #MASH #GLP1 #RNAi #DrugDiscovery #PreclinicalResearch 

✨Join Biocytogen at #AETEU 2026 in Basel, Switzerland! We’re excited to be part of Antibody Engineering & Therapeutics Europe 2026 from May 27–29, where leading scientists and industry partners come together to advance antibody innovation. 🔬 Meet us at Booth 22 to learn more about our fully human antibody discovery platforms and BioMice™ in vivo pharmacology models, supporting next-generation antibody discovery and preclinical therapeutic programs. 📅 May 27–29, 2026 📍 Congress Center, Basel, Switzerland We look forward to connecting with researchers, partners, and innovators shaping the future of antibody therapeutics. See you in Basel! #Biocytogen #AETEU #AETEU2026 #Bioconjugates #DrugDiscovery #AntibodyDiscovery #Biotech

🎥 Webinar Highlight: Preclinical Mouse Models for Obesity & Cardiovascular Disease Therapeutic Discovery Check out this short clip from our latest webinar and explore the full recording for deeper insights: https://lnkd.in/emVyr_rd 💡 Stay tuned for our upcoming webinar: RenNano Heavy-Chain-Only Antibodies for BBB crossing, multispecific antibodies, ADCs, and in vivo CAR-T therapies. 📅 May 27, 2026 | 11:00 AM ET 🔗 Register here: https://lnkd.in/eD7jaHWc #Biocytogen #Webinar #DrugDiscovery #PreclinicalResearch #MouseModels #CardiovascularResearch #ObesityResearch #AntibodyDiscovery #Biotechnology #Immunology #ADCs #CART #BBB #LifeSciences